Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: H. Lundbeck A/S Clear all
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.

NCT03287869
View directory record Official record
Conditions
Bipolar I Disorder, Acute Mania
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
44
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

NCT04405323
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06466, Itraconazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 1 Interventional

A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab

NCT04537429
View directory record Official record
Conditions
Migraine in Children, Migraine
Interventions
Eptinezumab
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
6 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Stamford, Connecticut • Gulf Breeze, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 17, 2026, 3:00 AM EDT
Withdrawn Phase 3 Interventional

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

NCT02174094
View directory record Official record
Conditions
Dravet Syndrome
Interventions
Clobazam, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
1 Year to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
8
States / cities
Los Angeles, California • Orlando, Florida • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

NCT02006654
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
26
States / cities
Mesa, Arizona • Bellflower, California • Costa Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

NCT03238326
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
17
States / cities
Dothan, Alabama • Anaheim, California • Culver City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

NCT01942785
View directory record Official record
Conditions
Major Depressive Disorder, Irritability
Interventions
Brexpiprazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
15
States / cities
Tucson, Arizona • Glendale, California • Oakland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 17, 2026, 3:00 AM EDT
Completed No phase listed Observational

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

NCT00936676
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
Not listed
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 1 Interventional Results available

Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700

NCT02333487
View directory record Official record
Conditions
Schizophrenia
Interventions
Lu AF35700
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 17, 2026, 3:00 AM EDT
Terminated Phase 1 Interventional

A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis

NCT04990219
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Lu AG06466, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Denver, Colorado • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder

NCT03257865
View directory record Official record
Conditions
Bipolar I Disorder, Manic Episode
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Little Rock, Arkansas • Bellflower, California • Cerritos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

NCT03594123
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 91 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 17, 2026, 3:00 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Trial of Lu AH69593 in Healthy Participants

NCT07775261
View directory record Official record
Conditions
Healthy Participants
Interventions
Lu AH69593, Itraconazole, Carbamazepine, Midazolam
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 3:00 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

NCT03230864
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Lu AF35700, Risperidone, Olanzapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

NCT03198078
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole (OPC-34712), Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

NCT03259555
View directory record Official record
Conditions
Bipolar I Disorder, Manic Episode
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 1 Interventional

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

NCT03292848
View directory record Official record
Conditions
ADHD, Autism, Bipolar I Disorder, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men

NCT04713254
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06466, Midazolam, Metoprolol, Bupropion
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

NCT02006641
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 1 Interventional

Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)

NCT04597450
View directory record Official record
Conditions
PTSD
Interventions
Lu AG06466, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 17, 2026, 3:00 AM EDT
Terminated Phase 2Phase 3 Interventional

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

NCT00040404
View directory record Official record
Conditions
Parkinson Disease
Interventions
CEP-1347 10mg, CEP1347 25mg, CEP-1347 50mg, Placebo Comparator
Drug · Other
Lead sponsor
Cephalon
Industry
Eligibility
30 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
56
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 17, 2026, 3:00 AM EDT
Completed No phase listed Observational

Assessment of Suicidality in Epilepsy - Rating Tools

NCT01085461
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
The Epilepsy Study Consortium
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

NCT01683058
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Carson, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 17, 2026, 3:00 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

NCT03446807
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions
Droxidopa, Placebo Oral Tablet
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 17, 2026, 3:00 AM EDT